Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Rodriguez-Ruiz

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Neuro-Oncology Advances|August 22, 2025
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastomaJames R Whittle, Maria Vieito, Kristoffer Rohrberg, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Science Translational Medicine|October 15, 2020
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumorsIván Márquez-Rodas, Federico Longo, Maria E Rodriguez-Ruiz, et al.
Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.
Pageof 4